Form 4: BVF Partners and Affiliates Boost Stake in Kymera Therapeutics Through Public Offering and Option Grants

BVF Partners L.P. and its affiliated entities, including Mark N. Lampert, have significantly increased their beneficial ownership in Kymera Therapeutics, Inc. by acquiring over 317,000 shares in a public offering and receiving new stock options.

Summary

• BVF Partners L.P., Biotechnology Value Fund L.P., Biotechnology Value Fund II, L.P., Biotechnology Value Trading Fund OS LP, and other affiliated entities, along with Mark N. Lampert, collectively increased their beneficial ownership in Kymera Therapeutics, Inc. (KYMR).
• On June 30, 2025, the reporting persons acquired a total of 317,167 shares of Common Stock at a price of $44.00 per share through an underwritten public offering.
• Following these transactions, Biotechnology Value Fund L.P. directly owns 2,798,795 shares, Biotechnology Value Fund II, L.P. directly owns 2,219,858 shares, and Biotechnology Value Trading Fund OS LP directly owns 353,412 shares.
• On June 25, 2025, 16,000 stock options were acquired with an exercise price of $46.47 per share, which will vest in full upon the earlier of June 25, 2026, or the date of the next annual meeting of stockholders, and expire on June 24, 2035.
• The reporting persons also hold various pre-funded warrants to purchase Common Stock at an exercise price of $0.0001, which are exercisable at any time and do not expire, totaling 1,337,282 shares underlying these warrants.
• Additionally, existing stock options for a total of 100,190 shares are held, with exercise prices ranging from $14.18 to $49.1, all of which are fully vested.

Sentiment

Score: 8

Explanation: The document indicates significant insider buying by a major institutional investor group, which is a strong positive signal of confidence in the company's future. This direct investment, especially following a public offering, suggests a belief in the current valuation and growth potential.

Positives

• Significant insider buying by a major institutional investor group (BVF Partners and affiliates) signals strong confidence in Kymera Therapeutics' future prospects.
• The acquisition of shares through a public offering at $44.00 per share demonstrates a direct financial commitment at a specific valuation.
• The grant of new stock options to a director associated with the reporting group aligns interests with long-term company performance.

Future Outlook

The document does not provide explicit forward-looking statements or guidance regarding the company's future performance or strategic direction, beyond the vesting schedule for newly granted stock options.

Management Comments

• The reporting persons, including BVF Partners L.P., BVF Inc., and Mark N. Lampert, are deemed to be directors by deputization of Kymera Therapeutics, Inc. due to Gorjan Hrustanovic's service on the Board of Directors and his agreement to transfer economic benefits from his options to Partners.
• Each of the reporting persons disclaims beneficial ownership of the securities reported except to the extent of their pecuniary interest therein.

Industry Context

Insider purchases, especially by significant institutional investors like BVF Partners, are often interpreted as a positive signal within the biotechnology and pharmaceutical industries, indicating confidence in the company's pipeline, clinical progress, or market potential, particularly following a public offering.

Corporate Governance

Related Party Transactions

• An agreement exists between BVF Partners L.P. and Gorjan Hrustanovic, a director of Kymera Therapeutics and a member of Partners, under which Mr. Hrustanovic is obligated to transfer the economic benefit received upon the sale of shares issuable from his stock options to Partners. This arrangement results in BVF Partners, BVF Inc., and Mark N. Lampert being deemed to have a pecuniary interest in these securities.

Stakeholder Impact

• Shareholders may view the significant insider buying by a major institutional investor as a positive indicator, potentially increasing investor confidence and demand for the stock.
• The clarification of board representation through deputization reinforces the alignment of interests between a key institutional investor and the company's strategic direction.

Next Steps

• The 16,000 stock options acquired on June 25, 2025, are expected to vest in full upon the earlier of June 25, 2026, or the date of the next annual meeting of Kymera Therapeutics' stockholders.

Key Dates

Recommendation

Keywords

Kymera Therapeutics, KYMR, BVF Partners, Insider Buying, Beneficial Ownership, Stock Options, Pre-Funded Warrants, Public Offering, SEC Form 4, Biotechnology, Investment Fund